New weight-loss drug dubbed the ‘triple G’ appears even MORE powerful than Ozempic, Wegovy, and Mounjaro – shedding 25% of patients’ bodyweight
- The new injectable led to weight loss of nearly 25 percent, the most of any drug
- The drug is still in the middle stages and phase 3 is currently enrolling patients
- READ MORE: Hate needles? Ozempic PILLS could be rolled out within MONTHS
Pharmaceutical giant Eli Lilly announced its obesity-busting drug could offer even greater weight loss benefits than Ozempic and Wegovy.
The Indiana-based company announced results from its mid-stage trial of its next-generation obesity drug candidate ‘retatrutide’, which led to 24.2 percent weight loss after 48 weeks, the greatest amount seen yet with any obesity medicine.
The once-weekly injectable has been dubbed ‘triple g’ because it targets three different hormones, compared to Ozempic and Wegovy which target one, and Eli Lilly’s other weight-loss drug Mounjaro, which targets two hormones.
Retatrutide is part of a class known as incretins, designed to mimic the action of hormones in the gut to help regulate blood sugar, slow stomach emptying and decrease appetite.
Lilly’s triple g, if approved, would join a growing field of revolutionary pills and injections such as Novo Nordisk’s Wegovy to help chronically overweight and obese people lose weight and improve their overall health.
Eli Lilly’s trial results, published in the New England Journal of Medicine, followed 338 overweight and obese adults for 48 weeks. Those taking the highest dose of the weekly injection – 12 mg – shed nearly 25 percent of their bodyweight by the study’s end
Semaglutide, marketed as Wegovy (shown here) is one in a growing number of medications for obesity currently revolutionizing the field
Lilly’s trial enrolled 338 adults who had a body mass index of 30 or higher (indicative of obesity) or who had a BMI of 27 (considered overweight) with at least one weight-related underlying condition.
The subjects, roughly half of whom were male and half were female, were broken into distinct groups that either received a placebo or one of four doses of retatrutide as a weekly injection.
After 24 weeks, patients on 12mg, the highest dose, lost an average 17.5 percent of their body weight, the equivalent of about 41 pounds.
At 48 weeks, that amount of weight lost had increased to 24.2 percent, roughly 58 pounds.
The most common adverse reactions were gastrointestinal, such as diahrrea and constipation. These also happen to be the most oft-reported side effects for injectable Wegovy and Ozempic.
Dan Skovronsky, Lilly’s chief scientific and medical officer, said: ‘These phase 2 data have given us confidence to further explore the potential of retatrutide in phase 3 trials that will look beyond weight reduction and focus on treating obesity and its complications comprehensively.’
The new family of drugs has reignited interest in the weight-loss treatment market, which is estimated to reach $100 billion by the end of the decade.
At the end of 48 weeks, the amount of weight lost had not plateaued, which suggests the subjects could have lost even more weight had they stayed on the medicine for longer
Lilly’s Mounjaro, which is awaiting U.S. regulatory approval for treatment of obesity, targets GLP-1 as well as a second obesity-related hormone called GIP.
The company reported last year that a trial of Mounjaro in people who were obese or overweight found it led to weight loss of 22.5 percent after 72 weeks.
Retatrutide targets GLP-1, GIP and the body’s receptors for a third hormone, glucagon.
Given the three targets, retatrutide has earned the moniker triple G.
Lilly is conducting longer-duration phase 3 trials of retatrutide to see if weight loss might be further improved. It is expected that remaining on the drug for longer than 48 weeks could lead to even more weight loss.
Those studies will evaluate the drug’s safety and effectiveness for chronic weight management as well as obstructive sleep apnea and knee osteoarthritis.
Results from the phase 2 trial were presented in San Diego at a meeting of the American Diabetes Association and published in the New England Journal of Medicine.
Big Pharma’s obesity gold rush: everything you need to know
Anti-obesity drugs like Novo Nordisk’s Wegovy could be the pharma industry’s biggest golden ticket yet – with some analysts forecasting the burgeoning industry will rake in over $100 billion in profits in the coming decade.
Also revealed at the ADA meeting were results from two gold-standard trials funded by Novo Nordisk into pill versions of its groundbreaking obesity drug Wegovy.
The first trial pertained to a pill version for people with type 2 diabetes. About 1,600 patients being treated for diabetes were broken into three groups and given daily 14mg, 25mg or 50mg doses.
Participants who took the two higher doses saw greater improvement in their blood glucose levels than those on the lower 14mg dose as well as greater reductions in body weight.
Starting at a baseline average weight of about 212 lbs., people taking either a 25mg or 50mg pill lost between 15 and 21 lbs after 68 weeks, compared to people who took a low dose and lost an average of 10 lbs.
The other trial pertained to people with overweight or obesity but not diabetes. The researchers tracked 667 people over 68 weeks, half of whom received a daily 50mg dose and the other half who received a dummy pill.
Those who took the pill lost an average of 15 percent of their body weight (about 35 lbs) at the end of the trial versus roughly 2.4 percent in placebo recipients.
The results showed that an oral version of the drug worked about as well as the injectable 2.4mg dose of Wegovy, which has been shown to successfully shave off up to 15 percent of a person’s body weight.
The development of triple g, whose approval could coincide closely with approval of Mounjaro for obesity, will add to an ever-growing arsenal against the plague of obesity, which affects nearly 40 percent of American adults.
Dr Shauna Levy, an obesity medicine specialist at Tulane University who attended the ADA meeting told DailyMail.com: ‘Obesity is a chronic disease that has been increasing in prevalence for years.
‘Treatment should be individualized for the patient, and more treatment options will allow us to better treat our patients.’
Source: Read Full Article